In the News
- Dr. Ramon Parsons elected into the National Academy of Medicine.
October 16, 2017
Ramon Parsons elected into the National Academy of Medicine. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
- Tisch Cancer Institute 2017 Town Hall
September 26, 2017
The Tisch Cancer Institute Town Hall gave an overview of the Cancer Center’s accomplishments, present state, and future goals. It was presented by Drs. Burakoff and Parsons to our faculty, staff, and trainees.
- RT Plus Chemo Triples PFS In Limited Metastatic Lung Cancer - Roxanne Nelson, BSN, RN
September 26, 2017
Accrual was halted early after an unplanned interim analysis found a significant improvement in PFS in the SAbR plus maintenance chemotherapy arm. In addition, rates of local control and delay in distant metastases favored combination therapy. Among patients who received consolidative local therapy, there were no recurrences in original sites of gross disease; there were seven failures in the patients who received only maintenance therapy. "This study is encouraging for patients suffering from metastatic lung cancer, as metastatic lung cancer is incurable, and the standard treatment is chemotherapy alone," commented Kenneth Rosenzweig, MD, professor and system chair of radiation oncology at the Icahn School of Medicine at Mount Sinai. "This study shows that treating small tumors with highly focused stereotactic radiation can improve survival with minimal toxicity and a high level of convenience," he said. "Since this study is so small, its results will need to be confirmed in a larger study."
- Kenneth Rosenzweig, MD, Professor, System Chair, Radiation Oncology, Icahn School of Medicine at Mount Sinai
- Mild Hypothermia During Prolonged Surgery May Reduce Complications
September 22, 2017
The ideal core temperature for patients undergoing prolonged major head and neck surgery remains unknown. Previous data indicates the low temperatures may increase the risk of developing postoperative complications such as tissue loss, hematomas, or surgical infections. A study done at The Mount Sinai Hospital looked at the core temperature of 519 patients during prolonged surgery for head and neck cancer in order to identify the optimal temperature range for these patients to prevent complications. The study found that higher intraoperative temperatures were associated with worse outcomes in terms of tissue loss, wound complications, and infection. Brett Miles, DDS, MD, FACS, associate professor of otolaryngology and head and neck surgery at the Icahn School of Medicine at Mount Sinai and co-chief in the division of head and neck oncology for the Mount Sinai Health System, said "Our study suggests an optimal temperature range of 35.3C-37.6C. If patients were above or below that range for a significant period of time, their complications increased. Therefore maintaining this temperature range (mild hypothermia) may improve flap outcomes in this population."
- Brett A. Miles, DDS, MD, FACS, Associate Professor, Otolaryngology, Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, Co-Chief, Division of Head and Neck Oncology, Fellowship Director, Otolaryngology-Head and Neck Surgery, Mount Sinai Health System
- Expert Discusses Approval of First CAR T-Cell Therapy - Danielle Bucco
September 18, 2017
The FDA's recent approval of tisagenlecleucel (Kymriah) as the first chimeric antigen receptor (CAR) T-cell Therapy, marks a new era in oncology. Tisagenlecleucel is specifically approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse, based on phase II results from the single-arm, international ELIANA trial. "Having the ability to genetically engineer a person's lymphocytes and essentially weaponize them to kill these cells is a huge advance," said James L. Ferrara, MD, DSc, professor of pediatrics, oncological sciences and medicine, hematology and medical oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and Co-director of Mount Sinai Acute GVHD International Consortium. It is likely that this therapy will extend to other subsets of leukemia and lymphoma, Dr. Ferrara added.
- James L.M. Ferrara, MD, DSc, Professor of Pediatrics, Oncological Sciences and Medicine, Hematology and Medical Oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, and Co-director of Mount Sinai Acute GVHD International Consortium (MAGIC)
- Gene Alterations Predict Response to Immunotherapy in Urothelial Carcinoma
September 13, 2017
Alterations in DNA damage repair and response genes appear to improve response to immune checkpoint blockade among patients with urothelial carcinoma, according to findings presented at the ASCO Annual Meeting. These results "clearly" indicate that such alternations could be "a potential predictive biomarker for response to immune checkpoint blockade," says Matthew Galsky, MD, associate professor of medicine, hematology and medical oncology, assistant professor of urology and the director of genitourinary medical oncology at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. "This is not ready for prime time, but there are ongoing, randomized clinical trials in the first-line setting in urothelial cancer, randomizing patients to chemotherapy alone vs. chemotherapy plus immune checkpoint blockade," Dr. Galsky said. "Those cohorts are ideally suited for testing this biomarker question."
- Matthew Galsky, MD, Associate Professor, Medicine, Hematology and Medical Oncology; Assistant Professor, Urology; Director, Genitourinary Medical Oncology, The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
- Extent of Remnant Liver Ischemia May Predict Survival After Colorectal Liver Metastases - Marilynn Larkin
September 8, 2017
A greater degree of remnant liver ischemia (RLI) after hepatic resection may be a significant predictor of worse recurrence-free and cancer-specific survival in patients who undergo curative resection of colorectal metastases (CLMs), researchers say. Sander Florman, MD, director of the Recanati/Miller Transplantation Institute at Mount Sinai and professor of surgery at the Icahn School of Medicine at Mount Sinai told Reuters Health, "This is an interesting manuscript, and the findings merit publication and consideration. The authors acknowledge the limitations of the study well and also correctly conclude that high-quality surgical techniques are imperative to successful curative liver surgery for colorectal carcinoma metastases."
- Sander Florman, MD, Director, Recaanti/Miller Transplantation Institute, Professor, Surgery, Icahn School of Medicine at Mount Sinai
As Cancer Patients Look To Last-Chance Therapies, Hard Conversations Are Getting Postponed - Bob Tedeschi
September 1, 2017
A new generation of immune-boosting therapies has been hailed as nothing short of revolutionary, shrinking tumors and extending lives. When late-stage cancer patients run out of other options, some doctors are increasingly nudging them to give immunotherapy a try. But that advice is now coming with unintended consequences. Doctors who counsel immunotherapy, experts say, are postponing conversations about palliative care and end-of-life wishes with their patients - sometimes, until it's too late. Cardinale Smith, MD, associate professor of medicine, hematology and medical oncology, geriatrics, and palliative medicine at the Icahn School of Medicine at Mount Sinai, said she has seen a handful of patients who tried immunotherapy treatments after failing chemotherapy, and who were later admitted to the hospital in poor condition. Almost all of them died there, without having been asked about where, and under what conditions, they might prefer to die. "These conversations are not occurring because of the hope that this will be the miracle treatment," Dr. Smith said. "Unfortunately, on the part of the oncologist, treatments like immunotherapy have become our new Hail Mary." Immunotherapies work for only around 15 to 20 percent of cancer patients who receive them.
- Cardinale Smith, MD, Associate Professor, Medicine, Hematology and Medical Oncology, Geriatrics, Palliative Medicine, Icahn School of Medicine at Mount Sinai
Ramon Parsons Named Director Of The Tisch Cancer Institute At Mount Sinai
August 31, 2017
Ramon Parsons, MD, PhD, professor and chair of oncological sciences at the Icahn School of Medicine at Mount Sinai was recently named the director of The Tisch Cancer Institute at Mount Sinai. One of Dr. Parsons' most important discoveries is the identification of PTEN, a tumor suppressor gene that is often mutated in cancer, which provides critical therapeutic targets in breast, brain, prostate, and endometrial cancer. In his new role as director of The Tisch Cancer Institute at Mount Sinai, Dr. Parsons will retain his role as chair of the Department of Oncological Sciences and will continue his research program.
- Ramon Parsons, MD, PhD, Director, The Tisch Cancer Institute at Mount Sinai, Professor, Chair, Oncological Sciences, Icahn School of Medicine at Mount Sinai
Cancer Patients Write To Heal In Unique Writing Workshop - Fran Lowry
August 22, 2017
A special writing workshop for cancer patients, cancer survivors, and caregivers is helping them to process their experiences through a safe and creative outlet. The Cancer Supporting Services Program at Mount Sinai Cancer Center offers weekly workshops overseen by Emily Rubin, an author and cancer survivor. Rubin uses prompts and quotes to get the creative juices flowing in her writers. "Participants do not need to have writing experience, and often caregivers are encouraged to participate. Participants utilize the time to share thoughts about cancer or take time out to not think about treatment and side effects," said Allison Snow, PhD, assistant director of cancer supportive services at the Mount Sinai Hospital.
- Alison Snow, PhD, Assistant Director, Cancer Supportive Services, The Mount Sinai Hospital
- Vitamin C Slows Leukemia In Mice By Tweaking Key Gene - Emma Laycock
August 21, 2017
High doses of vitamin C may help fight certain leukemias by boosting the activity of a particular gene, according to a new study. Daily injections of vitamin C slowed the progression of leukemia in mice with a faulty gene called TET2, and increased efficiency in the drug treatment. "If these findings withstand clinical testing, the impact for patients with blood cancers could be significant," said Eirini Papapetrou, MD, PhD, associate professor of oncological sciences, medicine, hematology, and medical oncology, at the Icahn School of Medicine at Mount Sinai.
- Eirini Papapetrou, MD, PhD, Associate Professor, Oncological Sciences, Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai
- Vitamin C Blocks Leukemia Progression In Mice — Aggie Mika
August 17, 2017
Researchers have halted the progression of leukemia in mice by restoring the enzyme TET2 in hematopoietic stem cells, either by reestablishing its gene expression in transgenic mice or by promoting the protein’s function with high doses of vitamin C. In a small experiment, vitamin C injections also suppressed leukemia progression in immunocompromised mice transplanted with hematopoietic stem cells from two leukemia patients. “If these findings withstand clinical testing, the impact for patients with blood cancers could be significant,” said Eirini Papapetrou, MD, PhD, associate professor of oncological sciences, medicine, hematology, and medical oncology, at the Icahn School of Medicine at Mount Sinai. “These patients have currently limited therapeutic options, particularly the more elderly patients, who cannot tolerate highly toxic treatment, like high-dose chemotherapy or bone marrow transplantation.”
-Eirini Papapetrou, MD, PhD, Associate Professor, Oncological Sciences, Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai
- Comparing Male And Female Breast Cancer — Charles Shapiro, MD
August 14, 2017
Men have breast tissue too, and some of them will develop breast cancers. Estimates of the annual incidence of invasive breast cancer in men in 2017 are just less than 2,500 cases, or 1 in 1,000 men over their lifetime. In contrast, the incidence of invasive breast cancer in women in the United States is about 253,000, or 1 in 8 women over the course of a lifetime. The primary risk factors for breast cancer in men and women are similar, with one exception. Common to both sexes is aging, although the average age at presentation is slightly older in men about 66, versus 61 years in women. Charles Shapiro, MD, director of cancer survivorship and translational breast cancer research at the Tisch Cancer Institute and professor of medicine at the Icahn School of Medicine at Mount Sinai said, “Perhaps the most interesting aspect of male breast cancer is the higher frequency of inherited genetic mutations in predisposing breast cancer genes of known importance in female breast cancers.”
- Charles Shapiro, MD, Director, Cancer Survivorship, Translational Breast Cancer Research, The Tisch Cancer Institute, Professor, Medicine, Icahn School of Medicine at Mount Sinai
- Answers To 'Critical Questions' May Personalize Treatment Of HPV-Associated Head, Neck Cancer
August 10, 2017
Prevalence of head and neck cancers increased from 30,000 total cases in 1996 to 50,000 in 2016. It is difficult to determine the primary cause of this trend because of the nature of how the virus develops and spreads, said Krzysztof Misiukiewicz, MD, associate professor of medical oncology an otolaryngology at the Icahn School of Medicine at Mount Sinai and HPV program for men at the Mount Sinai Center for Head and Neck Cancer. "We know that it takes at least 10 years from exposure of the virus to develop cancer. There are no proven reasons why this prevalence is occurring, but some ideas include migration - there is increased incidence of the infection in other areas or the world - lack of public awareness, and moving away from the traditional model of sexual partners" added Dr. Misiukiewicz. Raising awareness about vaccination should be a priority for clinicians.
- Krzysztof Misiukiewicz, MD, Associate Professor, Medical Oncology, Assistant Professor, Otolaryngology, Icahn School of Medicine at Mount Sinai, HPV Program for Men, Mount Sinai Center for Head and Neck Cancer
- Cancer Survivors More Likely To Be Prescribed Opioids Even Years Later - Alexa Mieses, MD
August 7, 2017
As if battling cancer wasn't enough, many long-term survivors may eventually find themselves dealing with opioid dependency, according to a new study. Cancer survivors are substantially more likely to be prescribed opioid painkillers over many years. Prescription opioids, which are in the same class as illicit heroin, are often indicated and prescribed for pain during cancer treatment and recovery. "This article highlights a dilemma about those long-term survivors who are on chronic opioids, and maybe we should take a harder look at them in terms of pain management," said Charles Shapiro, MD, director of cancer survivorship and translational breast cancer research at The Tisch Cancer Institute and professor of medicine at the Icahn School of Medicine at Mount Sinai. "But we often don't have the resources to take that harder look. It is important not to discount the usefulness of opioids for helping cancer patients manage serious, sometimes debilitating pain." We can't lose the message that opioids are indicated for that group with chronic pain and they work well, Dr. Shapiro added.
- Charles Shapiro, MD, Director, Cancer Survivorship, Translational Breast Cancer Research, The Tisch Cancer Institute, Professor, Medicine, Icahn School of Medicine at Mount Sinai
- Six Warning Signs Of Stomach Cancer That Have Nothing To Do With Pain - Markham Heid
August 4, 2017
Stomach cancer has a reputation for being one of the most painful forms of cancer. But for many sufferers, pain is not among the disease's early warning signs. In fact, the most common feature of stomach cancer's early stages may be that it causes no symptoms at all, says Umut Sarpel, MD, an associate professor of surgery at the Icahn School of Medicine at Mount Sinai. "We all get stomachaches from time to time, and that can make people worry about stomach cancer," said Dr. Sarpel. "But it's not one of the most common cancers, and in most cases stomachaches or pain are not going to be the result of cancer."
- Umut Sarpel, MD, Associate Professor, Surgery, Icahn School of Medicine at Mount Sinai
- Medscape - Essential Cancer Updates For Primary Care Physicians - Liam Davenport
August 4, 2017
The American Society of Clinical Oncology Annual Meeting not only provides a focus for cancer specialists looking for updates on state-of-the-art treatments and novel therapies but also presents research directly related to primary care physicians. William Oh, MD, professor of medicine, hematology, medical oncology, and urology at the Icahn School of Medicine at Mount Sinai provides takeaways on how the findings could influence primary care. The findings included helping smokers navigate skin cancer screening, which can improve detection rates. "We know that over the past few years, randomized trials have demonstrated the benefit of lung cancer screening in smokers. In this study, there was evidence that this approach really worked, particularly in community health centers, where lower-income smokers may not have the same access to some of the lung cancer screening guidelines as patients in private centers," said Dr. William Oh, Professor, Medicine, Hematology, Medical Oncology, Urology, Icahn School of Medicine at Mount Sinai.
Healio -FDA Approves Imbruvica As First Therapy For Chronic Graft-Versus-Host Disease - James L.M. Ferrara, MD, DSc
August 2, 2017
The FDA approved ibrutinib for the treatment of adults with chronic graft-versus-host disease who failed prior systemic therapy. "Chronic GVHD is a major toxicity of bone marrow transplant, which is one of the most effective therapies we have for high-risk malignancies. Both patients and physicians are reluctant to undertake transplantation, not only because of its initial intensity, but because of some of the long-term toxicities. Even if patients are cured of their leukemia or lymphoma, they can end up with this immune-mediated disease that can affect their skin, liver, lungs, gastrointestinal tract and joints. When it is severe, it can be fatal. It is the dark side of the therapy," says author of perspective James L. M. Ferrara, MD, professor of oncological sciences at the Icahn School of Medicine at Mount Sinai.
- CBS New York - A Deep Dive: The Breast Cancer Pill— Pat Farnack
July 31, 2017
Research of a new breast cancer pill, Olaparib, found that it can be used to treat a certain rare form of breast cancer. Charles Shapiro, MD, director of cancer survivorship and translational breast cancer research at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai said, ”the more we take a deep dive into the growth of these cells, the more we find that these breast cancers are different. Each woman has a unique breast cancer, instead of targeting that cancer with chemotherapy; we need to find the actual defect and targeting therapy based on the genes that make the tumor thick.” This breast cancer pill can be given to certain breast cancer populations instead of chemotherapy. - Charles Shapiro, MD, Director, Cancer Survivorship, Translational Breast Cancer Research, The Tisch Cancer Institute, Professor, Medicine, Icahn School of Medicine at Mount Sinai
- Medscape - "Noninvasive Urine Test Predicts Bladder Cancer Recurrence" - Roxanne Nelson
July 21, 2017
- Mesothelioma Research News - "New-Generation Radiation Combined With Surgery Is Effective Against Mesothelioma" - Iqra Mumal
July 20, 2017
- The Sentinel - "Astounding’ Second-Chance Cancer Drug Heading For FDA Approval" - Michael Nedelman
July 20, 2017
- Mount Sinai’s High-Resolution Imaging Allows Researchers to Identify How an Aggressive Skin Cancer Metastasizes
July 11, 2017
- Huffington Post - "Marilu Henner talks about Bladder Cancer" - Teresa Kindred
May 22, 2017
- New York Post - "How Assembling The Right Cancer Team May Save Your Life" - Heidi Mitchell
May 9, 2017
- Life Science Daily - "Immunotherapy Also Beneficial To Early-Stage Lung Cancer Patients, According To Study"
May 9, 2017
- Benzinga - "Pershing Shows It Isn't Done With The Biotech World After Valeant" - Elizabeth Balboa
May 8, 2017
- Crain's New York Health Pulse - "Pershing Prize"
May 8, 2017
- STAT - "Lab Chat: A new use for immunotherapy?" - Andrew Joseph
May 5, 2017
- TCI Endorses HPV Vaccine
January 27, 2016
- The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation
July 30, 2015
- Mount Sinai Receives $8.8 million Grant to Further Stem Cell Research
April 7, 2015
An $8.8 million grant from the New York State Stem Cell Science Program will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem-cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders.
- Mount Sinai Researchers Discover Genetic Origins of Myelodysplastic Syndrome Using Stem Cells
March 27, 2015
Findings Shed Light on the Development of Blood Cancers
- Test Predicts Response to Early Treatment for Dangerous Complication of Stem Cells Transplants Used in Leukemia Patients
December 23, 2014 Findings Could Guide More Precise Treatment of Graft Versus Host Disease
- New Signaling Role for Key Protein May Contribute to Wound Healing, Tumor Growth and Inflammatory Diseases
December 5, 2014
- Cardio-Oncology Clinic Established at The Mount Sinai Hospital
April 15, 2014 Cardiologists and cancer experts at The Mount Sinai Hospital have joined forces to establish its first Cardio-Oncology Clinic at The Tisch Cancer Institute.
- CBS News - "How Fruit Flies May Be the Key In the Fight Against Cancer"
February 16, 2014
- The American Society of Clinical Oncology Awards Quality Certification to Mount Sinai’s GI Medical Oncology Program at The Tisch Cancer Institute
October 30, 2013 Mount Sinai is the first only site in Manhattan with a QOPI®-certified practice.
- Mount Sinai Oncologists Improve Quality of Care for Cancer Patients with Standardized Criteria for Palliative Care Consultation
October 29, 2013 Intervention doubled palliative care consultations; lowered in-hospital mortality and hospital readmission rates.
- Mount Sinai Researchers Identify Mechanisms and Potential Biomarkers of Tumor Cell Dormancy
October 28, 2013 May be able to recreate conditions that keep cancer cells from growing after they have spread.
- Mount Sinai Receives NIH Grant to Increase the Engagement of African Americans in Colorectal Cancer Screening
September 4, 2013 Mount Sinai researchers have received a grant from the NIH to determine why African Americans are less likely than others to receive colorectal cancer screenings.
- The Mount Sinai Medical Center Launches Real-Time Patient-Feedback Survey Tool
July 31, 2013 Visitors to the Derald H. Ruttenberg Treatment Center first to use app assessing patient satisfaction
- The Mount Sinai Medical Center Recognized by U.S. News and World Report in Annual “Best Hospitals” Rankings
July 16, 2013 The Mount Sinai Medical Center is prominently featured in U.S. News & World Report’s clinical specialty ranking of the nation’s most outstanding hospitals.
- 400 Individuals Received Complimentary On-Site Melanoma Screenings at 2013 Aspen Ideas Festival
July 3, 2013 Mount Sinai dermatologists identified several melanomas and non-melanoma skin cancers at the screening.
- The Mount Sinai Medical Center Will Participate in the Aspen Ideas Festival
June 24, 2013 Kenneth Davis, MD, President and CEO of The Mount Sinai Medical Center, to speak on the future of medicine at the Aspen Ideas Festival in Colorado
- Gene Variant May Provide Novel Therapy for Several Cancer Types
June 6, 2013 A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer.
- Mount Sinai Researchers to Present Landmark Studies at American Society of Clinical Oncology Meeting
June 1, 2013 Mount Sinai researchers present new data on HPV oral infection and melanoma predictors at ASCO
- Sarcoma Foundation of America Honors Robert G. Maki, MD, PhD, with the Nobility in Science Award
April 29, 2013 Dr. Maki was recognized for his committment to finding a cure for sarcoma, a cancer of the connective tissue including bone, cartilage, muscle, and fat.
- Mount Sinai Launches Phase III Clinical Trial of Novel, Personalized Vaccine for Newly-Diagnosed Kidney Cancer
April 17, 2013 Study will examine potential of investigational immunotherapy AGS-003 to improve survival when combined with standard kidney cancer treatment.
- Soy-Based Compound May Reduce Tumor Cell Proliferation In Colorectal Cancer
April 11, 2013 Mount Sinai presented new research in several cancer types at the American Association for Cancer Research Annual Meeting
- Ramon Parsons, MD, PhD, Named Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai
March 6, 2013 Stuart Aaronson, MD, will continue conducting transformative research at Mount Sinai as Founding Chair, Emeritus
- Protein Lost in Tumors Blocks Normal Cells From Being Reprogrammed into Stem Cells
March 5, 2013 Mount Sinai researchers identify mechanism that prevents cells from being reprogrammed into embryonic stem cells
- Head Caps with Electrodes May Treat Brain Cancer
February 25, 2013 Patients with aggressive brain tumors may be treated with a head cap that produces changes in electrical fields, as part of a clinical trial at Mount Sinai.
- Facts About Mount Sinai in Cancer Research and Treatment
December 14, 2012 The Mount Sinai Medical Center is a leader in patient-centered, multi-disciplinary cancer research and treatment.
- Leon and Norma Hess Center for Science and Medicine Opens at Mount Sinai
December 13, 2012 The state-of-the-art facility expands research capacity, fosters real-time collaboration; Mount Sinai also unveils a new brand and logo
- New Six-Gene Signature Can Predict Prostate Cancer Survival
October 9, 2012 Mount Sinai researchers have identified a six-gene model that determines prognosis in men with treatment-resistant prostate cancer.
- Mount Sinai School of Medicine Researchers Awarded “Provocative Questions” Grant from National Cancer Institute
September 20, 2012 Researchers are among a select group of scientists who have been recognized for their quest to answer the most pressing questions about cancer.
- Mount Sinai Researchers Unveil New Chemotherapy-Resistant Cancer Stem Cell
September 10, 2012 Scientists have discovered cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression.
- Mount Sinai Presents Research on Robotic Surgery and HPV at Head and Neck Cancer Meeting
July 25, 2012 Benefits of robotic surgery in smokers and nonsmokers and predictors of HPV-positive head and neck cancer presented at the 8th International Conference on Head and Neck Cancer.
- Mount Sinai Researchers Develop A Multi-Target Approach To Treating Tumors
June 7, 2012 Ross L. Cagan, Ph.D., Professor and Associate Dean at Mount Sinai School of Medicine, led the study.
- Mount Sinai Researchers Present Studies On Treatment Trends, Myeloma Vaccine, and Predictive Models at Cancer Meeting
May 17, 2012 Access to care, vaccine, treatment trends among landmark research at the 2012 American Society of Clinical Oncology meeting.
- Radiation After Surgery Does Not Extend Survival in Lung Cancer Subtype
February 13, 2012 Mount Sinai researchers have found that post-operative radiation therapy does not improve outcomes in older patients with locally advanced lung cancer.
- Chef Floyd Cardoz Wins Top Chef Masters and 100,000 Dollars on Behalf of Mount Sinai
June 16, 2011 Chef Cardoz won Top Chef Master’s grand prize of $100,000 on behalf of The Tisch Cancer Institute’s Young Scientist Cancer Research Fund at Mount Sinai.
- Alisan Goldfarb, MD Receives Prestigious Award from American Cancer Society
May 24, 2011 Dr. Goldfarb was recognized with the Physician of Distinction Award for outstanding contributions to clinical care in breast cancer
- Dubin Breast Center Now Offers Cutting-Edge 3D Mammography Technology
May 9, 2011 The Dubin Breast Center of The Tisch Cancer Institute is one of the first centers in the country to offer 3D mammography, allowing for earlier and more accurate breast cancer diagnosis.
- Researchers Estimate Environmentally-Induced Childhood Disease Cost At $76.6 Billion
May 4, 2011 New data show that, despite previous efforts to curb their use, toxic chemicals have a major impact on health care costs and childhood morbidity
- Carlos Cordon-Cardo, MD, PhD Named Chair of Department of Pathology at The Mount Sinai Medical Center
April 4, 2011 Dr. Cordon-Cardo, an expert in experimental pathology and molecular oncology, joins Mount Sinai as Chair of the Department of Pathology
- Mount Sinai Celebrates the “Topping Off” of the New Center for Science and Medicine Building
February 7, 2011 Set to open in 2012, CSM will bring nearly a half-million square-feet of new, state-of-the-art medical research and clinical facilities to Mount Sinai.
- Researchers from Mount Sinai School of Medicine Make Major Breakthrough in Melanoma Research
December 22, 2010 A discovery made by Mount Sinai researchers about the progression of melanoma could lead to new treatments.
- Mount Sinai Appoints Robert Maki, MD, PhD, As New Chief of Pediatric Hematology Oncology
December 14, 2010 Dr. Robert Maki named Mount Sinai Chief of Pediatric Hematology/Oncology and Medical Director, Sarcoma Cancer Program, at The Tisch Cancer Institute.
- Dr. AnaLisa DiFeo Recognized As Liz Tilberis Scholar for Ovarian Cancer Research
December 1, 2010 AnaLisa DiFeo honored with the Liz Tilberis Grant from the Ovarian Cancer Research Fund to support her research on chemoresistance in ovarian cancer.
- Conference to Explore Latest Screening Methods and Treatments for Lung Cancer
October 21, 2010 23rd International Conference on Screening for Lung Cancer To Be Held at The Mount Sinai Medical Center October 22 and 23
- The Mount Sinai Medical Center Appoints Randall F. Holcombe, MD As Director of Clinical Cancer Affairs
September 24, 2010 Dr. Randall Holcombe has joined Mount Sinai as Director of Clinical Cancer Affairs and Director of Gastrointestinal Medical Oncology.
- Dr. Marshall Posner Leads the Head and Neck Oncology Program at Mount Sinai
July 27, 2010 As the medical director, Dr. Posner will lead an interdisciplinary collaboration with surgery and continue his research on viral-driven solid tumor oncology.
- Jia Chen, ScD, Receives Visiting Scientist Award from International Agency for Research on Cancer
June 14, 2010 Dr. Chen will spend the 2010/2011 academic year continuing her research on breast and lung cancer with collaborators at IARC in Lyon, France.
- Raja Flores, MD, Named Chief of Thoracic Surgery at The Mount Sinai Medical Center
June 1, 2010 Dr. Raja Flores is the newest member of The Mount Sinai Cancer Center.
- Sundar Jagannath, MD, Named Director of Multiple Myeloma Program at Mount Sinai School of Medicine
June 1, 2010 Blood cancer expert Sundar Jagannath, MD, will join The Mount Sinai Medical Center as Director of the Multiple Myeloma Program.
- Elisa R. Port, MD, FACS, Named Chief of Breast Surgery at Mount Sinai School of Medicine
April 22, 2010 Renowned surgeon Elisa R. Port, MD, FACS, returns as Chief of Breast Surgery and Co-Director of the Dubin Breast Center.
- Robotic Prostatectomy Minimizes Surgery, Reduces Recovery Time, and Shortens Hospital Stays
April 15, 2010 Recent Mount Sinai study shows significant benefits to robotically assisted procedures over open prostate surgery.
- William K. Oh, MD, Joins The Mount Sinai Medical Center As Chief of the Division of Hematology and Medical Oncology
September 16, 2009 William K. Oh, MD, is known for his expertise in using biological data banks to advance the understanding of cancer and cancer treatment.
- Mount Sinai's State-of-the-Art Prostate Cancer Center Targets Quality of Life for Patients Undergoing Robotic Surgery
May 13, 2009 The resource center for prostate cancer care, led by David B. Samadi, MD, Chief of the Division of Robotics and Minimally Invasive Surgery, specializes in pre- and postsurgical care.
- Men with Prostate Cancer Worry Less About Recurrence Than Their Partners Do
April 23, 2009 Researchers at Mount Sinai have found that when it comes to worrying about the recurrence of prostate cancer, male patients worry less than their spouses or partners.